849 related articles for article (PubMed ID: 26837699)
1. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia.
Nadeu F; Delgado J; Royo C; Baumann T; Stankovic T; Pinyol M; Jares P; Navarro A; Martín-García D; Beà S; Salaverria I; Oldreive C; Aymerich M; Suárez-Cisneros H; Rozman M; Villamor N; Colomer D; López-Guillermo A; González M; Alcoceba M; Terol MJ; Colado E; Puente XS; López-Otín C; Enjuanes A; Campo E
Blood; 2016 Apr; 127(17):2122-30. PubMed ID: 26837699
[TBL] [Abstract][Full Text] [Related]
2. NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.
Chiaretti S; Marinelli M; Del Giudice I; Bonina S; Piciocchi A; Messina M; Vignetti M; Rossi D; Di Maio V; Mauro FR; Guarini A; Gaidano G; Foà R
Leuk Lymphoma; 2014 Dec; 55(12):2785-92. PubMed ID: 24597984
[TBL] [Abstract][Full Text] [Related]
3. Frequencies of SF3B1, NOTCH1, MYD88, BIRC3 and IGHV mutations and TP53 disruptions in Chinese with chronic lymphocytic leukemia: disparities with Europeans.
Xia Y; Fan L; Wang L; Gale RP; Wang M; Tian T; Wu W; Yu L; Chen YY; Xu W; Li JY
Oncotarget; 2015 Mar; 6(7):5426-34. PubMed ID: 25605254
[TBL] [Abstract][Full Text] [Related]
4. A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia.
Chauzeix J; Pastoret C; Donaty L; Gachard N; Fest T; Feuillard J; Rizzo D
Int J Lab Hematol; 2021 Aug; 43(4):683-692. PubMed ID: 33325634
[TBL] [Abstract][Full Text] [Related]
5. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia.
Rossi D; Rasi S; Spina V; Bruscaggin A; Monti S; Ciardullo C; Deambrogi C; Khiabanian H; Serra R; Bertoni F; Forconi F; Laurenti L; Marasca R; Dal-Bo M; Rossi FM; Bulian P; Nomdedeu J; Del Poeta G; Gattei V; Pasqualucci L; Rabadan R; Foà R; Dalla-Favera R; Gaidano G
Blood; 2013 Feb; 121(8):1403-12. PubMed ID: 23243274
[TBL] [Abstract][Full Text] [Related]
6. Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia.
Rasi S; Khiabanian H; Ciardullo C; Terzi-di-Bergamo L; Monti S; Spina V; Bruscaggin A; Cerri M; Deambrogi C; Martuscelli L; Biasi A; Spaccarotella E; De Paoli L; Gattei V; Foà R; Rabadan R; Gaidano G; Rossi D
Haematologica; 2016 Apr; 101(4):e135-8. PubMed ID: 26819056
[No Abstract] [Full Text] [Related]
7. THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT.
Bilous NI; Abramenko IV; Chumak AA; Dyagil IS; Martina ZV; Saenko V; Bazyka DA
Probl Radiac Med Radiobiol; 2018 Dec; 23():283-301. PubMed ID: 30582853
[TBL] [Abstract][Full Text] [Related]
8. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia.
Dal Bo M; Bulian P; Bomben R; Zucchetto A; Rossi FM; Pozzo F; Tissino E; Benedetti D; Bittolo T; Nanni P; Cattarossi I; Zaina E; Chivilò H; Degan M; Zaja F; Pozzato G; Chiarenza A; Di Raimondo F; Del Principe MI; Del Poeta G; Rossi D; Gaidano G; Gattei V
Leukemia; 2016 Oct; 30(10):2011-2018. PubMed ID: 27109509
[TBL] [Abstract][Full Text] [Related]
9. On the way towards a 'CLL prognostic index': focus on TP53, BIRC3, SF3B1, NOTCH1 and MYD88 in a population-based cohort.
Cortese D; Sutton LA; Cahill N; Smedby KE; Geisler C; Gunnarsson R; Juliusson G; Mansouri L; Rosenquist R
Leukemia; 2014 Mar; 28(3):710-3. PubMed ID: 24217197
[No Abstract] [Full Text] [Related]
10. Recurrent mutations refine prognosis in chronic lymphocytic leukemia.
Baliakas P; Hadzidimitriou A; Sutton LA; Rossi D; Minga E; Villamor N; Larrayoz M; Kminkova J; Agathangelidis A; Davis Z; Tausch E; Stalika E; Kantorova B; Mansouri L; Scarfò L; Cortese D; Navrkalova V; Rose-Zerilli MJ; Smedby KE; Juliusson G; Anagnostopoulos A; Makris AM; Navarro A; Delgado J; Oscier D; Belessi C; Stilgenbauer S; Ghia P; Pospisilova S; Gaidano G; Campo E; Strefford JC; Stamatopoulos K; Rosenquist R;
Leukemia; 2015 Feb; 29(2):329-36. PubMed ID: 24943832
[TBL] [Abstract][Full Text] [Related]
11. The impact of SF3B1 mutations in CLL on the DNA-damage response.
Te Raa GD; Derks IA; Navrkalova V; Skowronska A; Moerland PD; van Laar J; Oldreive C; Monsuur H; Trbusek M; Malcikova J; Lodén M; Geisler CH; Hüllein J; Jethwa A; Zenz T; Pospisilova S; Stankovic T; van Oers MH; Kater AP; Eldering E
Leukemia; 2015 May; 29(5):1133-42. PubMed ID: 25371178
[TBL] [Abstract][Full Text] [Related]
12. Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia.
Putowski M; Podgórniak M; Piróg M; Knap J; Zaleska J; Purkot J; Zawiślak J; Zakrzewska E; Karczmarczyk A; Własiuk P; Subocz E; Giannopoulos K
Pol Arch Intern Med; 2017 Apr; 127(4):238-244. PubMed ID: 28424451
[TBL] [Abstract][Full Text] [Related]
13. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2.
Strefford JC; Sutton LA; Baliakas P; Agathangelidis A; Malčíková J; Plevova K; Scarfó L; Davis Z; Stalika E; Cortese D; Cahill N; Pedersen LB; di Celle PF; Tzenou T; Geisler C; Panagiotidis P; Langerak AW; Chiorazzi N; Pospisilova S; Oscier D; Davi F; Belessi C; Mansouri L; Ghia P; Stamatopoulos K; Rosenquist R
Leukemia; 2013 Nov; 27(11):2196-9. PubMed ID: 23558524
[TBL] [Abstract][Full Text] [Related]
14. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.
Stilgenbauer S; Schnaiter A; Paschka P; Zenz T; Rossi M; Döhner K; Bühler A; Böttcher S; Ritgen M; Kneba M; Winkler D; Tausch E; Hoth P; Edelmann J; Mertens D; Bullinger L; Bergmann M; Kless S; Mack S; Jäger U; Patten N; Wu L; Wenger MK; Fingerle-Rowson G; Lichter P; Cazzola M; Wendtner CM; Fink AM; Fischer K; Busch R; Hallek M; Döhner H
Blood; 2014 May; 123(21):3247-54. PubMed ID: 24652989
[TBL] [Abstract][Full Text] [Related]
15. Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL.
Guièze R; Robbe P; Clifford R; de Guibert S; Pereira B; Timbs A; Dilhuydy MS; Cabes M; Ysebaert L; Burns A; Nguyen-Khac F; Davi F; Véronèse L; Combes P; Le Garff-Tavernier M; Leblond V; Merle-Béral H; Alsolami R; Hamblin A; Mason J; Pettitt A; Hillmen P; Taylor J; Knight SJ; Tournilhac O; Schuh A
Blood; 2015 Oct; 126(18):2110-7. PubMed ID: 26316624
[TBL] [Abstract][Full Text] [Related]
16. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
Rigolin GM; Saccenti E; Bassi C; Lupini L; Quaglia FM; Cavallari M; Martinelli S; Formigaro L; Lista E; Bardi MA; Volta E; Tammiso E; Melandri A; Urso A; Cavazzini F; Negrini M; Cuneo A
J Hematol Oncol; 2016 Sep; 9(1):88. PubMed ID: 27633522
[TBL] [Abstract][Full Text] [Related]
17. Prognostic correlation of NOTCH1 and SF3B1 mutations with chromosomal abnormalities in chronic lymphocytic leukemia patients.
Sadria R; Motamed N; Saberi Anvar M; Mehrabani Yeganeh H; Poopak B
Cancer Rep (Hoboken); 2023 Mar; 6(3):e1757. PubMed ID: 36411516
[TBL] [Abstract][Full Text] [Related]
18. IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.
Rizzo D; Chauzeix J; Trimoreau F; Woillard JB; Genevieve F; Bouvier A; Labrousse J; Poli C; Guerin E; Dmytruk N; Remenieras L; Feuillard J; Gachard N
Leukemia; 2015 Feb; 29(2):337-45. PubMed ID: 24943833
[TBL] [Abstract][Full Text] [Related]
19. ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.
Rose-Zerilli MJ; Forster J; Parker H; Parker A; Rodríguez AE; Chaplin T; Gardiner A; Steele AJ; Collins A; Young BD; Skowronska A; Catovsky D; Stankovic T; Oscier DG; Strefford JC
Haematologica; 2014 Apr; 99(4):736-42. PubMed ID: 24584352
[TBL] [Abstract][Full Text] [Related]
20. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.
Dreger P; Schnaiter A; Zenz T; Böttcher S; Rossi M; Paschka P; Bühler A; Dietrich S; Busch R; Ritgen M; Bunjes D; Zeis M; Stadler M; Uharek L; Scheid C; Hegenbart U; Hallek M; Kneba M; Schmitz N; Döhner H; Stilgenbauer S
Blood; 2013 Apr; 121(16):3284-8. PubMed ID: 23435461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
